Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan;129(2):282-290.
doi: 10.1111/1471-0528.16990. Epub 2021 Nov 18.

SARS-CoV-2 and pregnancy outcomes under universal and non-universal testing in Sweden: register-based nationwide cohort study

Affiliations

SARS-CoV-2 and pregnancy outcomes under universal and non-universal testing in Sweden: register-based nationwide cohort study

O Stephansson et al. BJOG. 2022 Jan.

Abstract

Objective: To assess associations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and pregnancy outcomes considering testing policy and test-positivity-to-delivery interval.

Design: Nationwide cohort study.

Setting: Sweden.

Population: From the Pregnancy-Register we identified 88 593 singleton births, 11 March 2020-31 January 2021, linked to data on SARS-CoV-2-positivity from the Public Health Agency, and information on neonatal care admission from the Neonatal Quality Register. Adjusted odds ratios (aORs) were estimated stratified by testing-policy and test-positivity-to-delivery interval.

Main outcome measures: Five-minute Apgar score, neonatal care admission, stillbirth and preterm birth.

Results: During pregnancy, SARS-CoV-2 test-positivity was 5.4% (794/14 665) under universal testing and 1.9% (1402/73 928) under non-universal testing. There were generally lower risks associated with SARS-CoV-2 under universal than non-universal testing. In women testing positive >10 days from delivery, generally no significant differences in risk were observed under either testing policy. Neonatal care admission was more common (15.3% versus 8.0%; aOR 2.24, 95% CI 1.62-3.11) in women testing positive ≤10 days before delivery under universal testing. There was no significant association with 5-minute Apgar score below 7 (1.0% versus 1.7%; aOR 0.64, 95% CI 0.24-1.72) or stillbirth (0.3% versus 0.4%; aOR 0.72, 95% CI 0.10-5.20). Compared with term births (2.1%), test-positivity was higher in medically indicated preterm birth (5.7%; aOR 2.70, 95% CI 1.60-4.58) but not significantly increased in spontaneous preterm birth (2.3%; aOR 1.12, 95% CI 0.62-2.02).

Conclusions: Testing policy and timing of test-positivity impact associations between SARS-CoV-2-positivity and pregnancy outcomes. Under non-universal testing, women with complications near delivery are more likely to be tested than women without complications, thereby inflating any association with adverse pregnancy outcomes compared with findings under universal testing.

Tweetable abstract: Testing policy and time from SARS-CoV-2 infection to delivery influence the association with pregnancy outcomes.

Keywords: Apgar; coronavirus disease 2019; neonatal care; preterm birth; severe acute respiratory syndrome coronavirus 2; stillbirth; universal.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Pregnancy outcomes by SARS‐CoV‐2 test‐positivity under universal and non‐universal testing in women testing positive within 10 and more than 10 days from delivery compared with women not testing positive during pregnancy.
Figure 2
Figure 2
Proportion of SARS‐CoV‐2‐positivity by gestational age at delivery under universal and non‐universal testing.
Figure 3
Figure 3
Forest plot comparing outcomes during March 2020 and January 2021 (pandemic period) versus between March 2015 and January 2020 (pre‐pandemic period; excluding February for all years). Live births with 5‐minute Apgar data: n = 91 407/90 632/91 672; total births: n = 476 166/473 929/477 788.

References

    1. Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta‐analysis. BMJ 2020;1:m3320. - PMC - PubMed
    1. Rasmussen SA, Jamieson DJ. Pregnancy, postpartum care, and COVID‐19 vaccination in 2021. JAMA 2021;325:1099. - PubMed
    1. Pettirosso E, Giles M, Cole S, Rees M. COVID‐19 and pregnancy: a review of clinical characteristics, obstetric outcomes and vertical transmission. Aust N Z J Obstet Gynaecol 2020;60:640–59. - PMC - PubMed
    1. Sutton D, Fuchs K, D'Alton M, Goffman D. Universal screening for SARS‐CoV‐2 in women admitted for delivery. N Engl J Med 2020;382:2163–4. - PMC - PubMed
    1. Ahlberg M, Neovius M, Saltvedt S, Soderling J, Pettersson K, Brandkvist C, et al. Association of SARS‐CoV‐2 test status and pregnancy outcomes. JAMA 2020;324:1782. - PMC - PubMed

Publication types

MeSH terms